Absci (ABSI) Other financing activities (2024 - 2026)
Absci (ABSI) posted Other financing activities of $59000.0 for Q1 2026, down 93.0% sequentially from $843000.0 in Q4 2025, and down 96.92% YoY from $1.9 million in Q1 2025.
Analysis
Absci (ABSI) Other financing activities (2024 - 2026) Analysis & Trends
Absci has reported Other financing activities for 3 years, with the latest figure at $59000.0 in Q1 2026.
- Quarterly Other financing activities fell 96.92% year-over-year to $59000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 million (down 67.25% YoY) and the FY2025 annual result came in at $3.3 million, down 20.41% from the prior year.
- Other financing activities eased to $59000.0 in Q1 2026 per ABSI's latest filing, from $843000.0 in the prior quarter.
- Over five years, Other financing activities peaked at $4.2 million in Q4 2024 and troughed at -$1.6 million in Q2 2024.
- A 3-year average of $941000.0 and a median of $647000.0 in 2025 frame the typical range for Other financing activities.
- The sharpest annual moves came in 2025 and 2026: Other financing activities surged 106.26% in 2025, then tumbled 96.92% in 2026.
- Over 3 years, Other financing activities stood at $4.2 million in 2024, then tumbled by 79.73% to $843000.0 in 2025, then slumped by 93.0% to $59000.0 in 2026.
- According to Business Quant data, Other financing activities over the past three periods registered $59000.0, $843000.0, and $451000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 10 | Absci | 1.38 Bn | 1.18 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.85 Mn |
| Mar 31, 2026 | 59,000.00 |
| Dec 31, 2025 | 843,000.00 |
| Sep 30, 2025 | 451,000.00 |
| Jun 30, 2025 | 102,000.00 |
| Mar 31, 2025 | 1.91 Mn |
| Dec 31, 2024 | 4.16 Mn |
| Jun 30, 2024 | -1.63 Mn |
| Mar 31, 2024 | 1.63 Mn |